Cover Image

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods: COVID-19 positive patients admitted to the ho...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mario Karolyi (Author), Sara Omid (Author), Erich Pawelka (Author), Bernd Jilma (Author), Thomas Stimpfl (Author), Christian Schoergenhofer (Author), Hermann Laferl (Author), Tamara Seitz (Author), Marianna Traugott (Author), Christoph Wenisch (Author), Alexander Zoufaly (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
by: M. Karolyi, et al.
Published: (2022)

Immunoglobulin G production in COVID-19 - associations with age, outcome, viral persistence, inflammation and pro-thrombotic markers
by: Anita Pirabe, et al.
Published: (2023)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
by: Ashish Chandwani, et al.
Published: (2008)

355 Lopinavir/ritonavir treatment in paediatric patients with covid-19
by: P Ip, et al.
Published: (2021)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018)

Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis
by: Bahman Amani, et al.
Published: (2021)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
by: Christiana Smith, et al.
Published: (2016)

Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials
by: Tejas K. Patel, et al.
Published: (2021)

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir
by: Yin, Guosheng, et al.
Published: (2020)

Melatonin and alpha lipoic acid restore electrolytes and kidney morphology of lopinavir/ritonavir-treated rats
by: Elias Adikwu, et al.
Published: (2020)

Amorphous solid dispersion formation via solvent granulation - A case study with ritonavir and lopinavir
by: Niraj S. Trasi, et al.
Published: (2019)

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection
by: Irin Tanaudommongkon, et al.
Published: (2021)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
by: Nils von Hentig, et al.
Published: (2021)

Propiedad intelectual y acceso a medicamentos:el caso de lopinavir/ritonavir en Guatemala
by: Luis Pablo Méndez-Alburez, et al.
Published: (2016)

Influence of traditional Chinese medicines on the in vivo metabolism of lopinavir/ritonavir based on UHPLC-MS/MS analysis
by: Linlin Li, et al.
Published: (2022)

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020)

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
by: Linhu Ye, et al.
Published: (2021)

A novel validated UPLC method for quantitation of lopinavir and ritonavir in bulk drug and pharmaceutical formulation with its impurities
by: Gnana Deepika Killi, et al.
Published: (2014)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020)

Functional Role of P-Glycoprotein and Binding Protein Effect on the Placental Transfer of Lopinavir/Ritonavir in the Ex Vivo Human Perfusion Model
by: Pierre-Francois Ceccaldi, et al.
Published: (2009)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
by: Vincenzo Russo, et al.
Published: (2020)

Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria
by: Sikiru Olatunji Usman, et al.
Published: (2020)

No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison
by: Roberta Gagliardini, et al.
Published: (2021)

Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis
by: Audrey Monnin, et al.
Published: (2021)

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
by: Bin Su, et al.
Published: (2019)

miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir
by: Elena Bresciani, et al.
Published: (2019)

Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
by: Yinqiu Huang, et al.
Published: (2018)

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week
by: Henri Gautier Ouedraogo, et al.
Published: (2020)

Experiencia del tratamiento con lopinavirritonavir en pacientes del programa de infección por VIH en un hospital universitario, Bogotá, Colombia Experience with lopinavir/ritonavir for patients with HIV infection at an university hospital in Bogotá, Colombia
by: JORGE ALBERTO CORTÉS, et al.
Published: (2006)

Drug-Drug Interactions in Patients with Acute Respiratory Distress Syndrome
by: Thorsten Bischof, et al.
Published: (2024)

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China
by: Peng-Le Guo, et al.
Published: (2021)

The Role of PXR Genotype and Transporter Expression in the Placental Transport of Lopinavir in Mice
by: Sarabjit S. Gahir, et al.
Published: (2017)

SARS-CoV-2 infections in "less visible" hospital staff: The roles and safety of environmental services and allied health professionals
by: Sebastian Jensen, et al.
Published: (2023)

Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir
by: Mitesh Patel, et al.
Published: (2014)

Do we need CBCTs for sufficient diagnostics?-dentist-related factors
by: Josipa Radic, et al.
Published: (2018)

Risk-pooling: necessary but not sufficient?
by: Davies Philip, et al.
Published: (2001)

Risk-pooling: necessary but not sufficient?
by: Philip Davies, et al.

Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data
by: Christoph Lübbert, et al.
Published: (2023)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023)

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
by: Ali A. Alhadab, et al.
Published: (2020)